Tweets
GiACTA part 2 - the morning has arrived! Disappointment or hope for tocilizumab in GCA? I'll be live tweeting it as we go.
Here's the abstract to start you off:
https://t.co/qtH8E5rVrB
#EULAR2019 OP0140 @RheumNow
David Liew @drdavidliew ( View Tweet )
7 years 2 months ago
Positive results presented so yes, interest in molecules beyond JAKi. All good for people esp once patents finish! #EULAR2019 https://t.co/beW9GblqdF
Dr Irwin Lim @_connectedcare ( View Tweet )
7 years 2 months ago
Look at this list of Biosimilars to TNFis! How would you decide what to use? The cost to the payer & what might be imposed? #EULAR2019 https://t.co/DhshdumsXO
Dr Irwin Lim @_connectedcare ( View Tweet )
7 years 2 months ago
In GCA, concomitant PMR might separate out better prognosis phenotype. Mortality benefit in PMR-relevant OR 0.68 (0.58-0.80). Phenotypes important moving forward in therapeutic selection? #EULAR2019 THU0295 from U La Paz, Madrid @RheumNow https://t.co/4viMygbTcP
David Liew @drdavidliew ( View Tweet )
7 years 2 months ago
Good morning #EULAR2019 delegates. Come by and visit, meet the Editor! https://t.co/DagNuxGfDq
The Journal of Rheumatology @jrheum ( View Tweet )
7 years 2 months ago
Cool data presented at #EULAR2019 by @CreakyJoints #ArthritisPower https://t.co/ZtFUsEiboR
Seth D. Ginsberg @SethSaidSo ( View Tweet )
7 years 2 months ago
Think: Do you really need to repeat another ANA test?🤔
👉🏼Repeat Antinuclear #antibody testing after a negative result had limited utility in diagnosis of ANA associated rheumatological conditions
Via Ai Li Yeo #EULAR2019 OP0020
@RheumNow
#immunology #rheumedu https://t.co/eK7GTRn8Z7
Dr Ai Lyn Tan @DrAiLynTan ( View Tweet )
7 years 2 months ago
OP0315. In ERA CATCH cohort fatigue final improvement lags behin remission by approx 6 months. So tell pts with RA that maximal improvement in fatigue lags a bit. #EULAR2019 @RheumNow
Janet Pope @Janetbirdope ( View Tweet )
7 years 2 months ago
New #EULAR2019 data finds a link between vitamin D deficiency and disease activity among #spondyloarthritis patients. This could help explain the cause of "osteoporosis related to spondyloarthritis, and may adversely affect the patient’s functional status and quality of life."
CreakyJoints.org @CreakyJoints ( View Tweet )
7 years 2 months ago
There is no clear relationship between ANCA titer and vasculitis relapse, but patients with negative ANCA seem to have less relapses. #EULAR2019 #vasculitis
Jesús Loarce @JesusLoarce ( View Tweet )
7 years 2 months ago
Congratulations to @Yuz6Yusof, awarded best #EULAR2019 abstract!
His work
👉🏼recommended monitoring immunoglobulins baseline & b4 rituximab cycles to identify patients at risk of severe infections https://t.co/bOdwVLlXnL
Dr Ai Lyn Tan @DrAiLynTan ( View Tweet )
7 years 2 months ago
Interesting discussion about nocebo effect when swapping to biosimilars. “Cheaper” may trigger this.
Health professionals need to understand we are salespeople in many situations. Language, trust, style matter.
#EULAR2019 https://t.co/29GP6cmXhQ
Dr Irwin Lim @_connectedcare ( View Tweet )
7 years 2 months ago
Optimal bimekizumab dose in PsA still remains to be determined.
Stefan Siebert @StefanSiebert1 ( View Tweet )
7 years 2 months ago
Ritchlin: Bimekizumab (anti-IL17A & F) Phase 2B in active PsA = rapid response but also further increases wk12 to wk20 and sustained to wk48.
#eular2019 @RheumNow https://t.co/yblCNmTxR4
Stefan Siebert @StefanSiebert1 ( View Tweet )
7 years 2 months ago
@_connectedcare @RheumNow Certainly good rationale for also blocking IL-17F from pathophysiology point of view but will need to see if leads to diffs in RCTs…may also be important for IBD/other conditions
Stefan Siebert @StefanSiebert1 ( View Tweet )
7 years 2 months ago
